347 related articles for article (PubMed ID: 21658624)
1. Radioimmunotherapy in follicular lymphoma.
Illidge T; Morschhauser F
Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
4. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
[TBL] [Abstract][Full Text] [Related]
5. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C
Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
7. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy in follicular lymphoma: some like it hot….
Kersten MJ
Transfus Apher Sci; 2011 Apr; 44(2):173-8. PubMed ID: 21334979
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life.
Andrade-Campos MM; Montes-Limón AE; Soro-Alcubierre G; Grasa JM; Lopez-Gómez L; Baringo T; Giraldo P
Ann Hematol; 2014 Dec; 93(12):1985-92. PubMed ID: 24985089
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Witzig TE
Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
[TBL] [Abstract][Full Text] [Related]
12. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
13. FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
Pisani F; Maini CL; Sciuto R; Dessanti L; D'Andrea M; Assisi D; Petti MC
J Exp Clin Cancer Res; 2011 Feb; 30(1):16. PubMed ID: 21303501
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
Ghobrial I; Witzig T
Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.
Puvvada SD; Guillén-Rodríguez JM; Yan J; Inclán L; Heard K; Rivera XI; Anwer F; Mahadevan D; Schatz JH; Persky DO
Oncology; 2018; 94(5):274-280. PubMed ID: 29471300
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
Juweid ME
J Nucl Med; 2002 Nov; 43(11):1507-29. PubMed ID: 12411555
[TBL] [Abstract][Full Text] [Related]
17. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Dillman RO
Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
[TBL] [Abstract][Full Text] [Related]
20. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
Aurer I; Huić D; Zuvić M; Sever-Prebilić M; Ajduković R; Radman I; Skare-Librenjak L; Ostojić-Kolonić S; Labar B
Lijec Vjesn; 2006; 128(7-8):224-7. PubMed ID: 17087138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]